A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

21.8K views

⸱

DOI:

10.3791/50429

⸱

June 28th, 2013

 ,  , 

In This Article

Summary

Pluripotent stem cells, either embryonic or induced pluripotent stem (iPS) cells, constitute a valuable source of human differentiated cells, including cardiomyocytes. Here, we will focus on cardiac induction of iPS cells, showing how to use them to obtain functional human cardiomyocytes through an embryoid bodies-based protocol.

Abstract

In order to investigate the events driving heart development and to determine the molecular mechanisms leading to myocardial diseases in humans, it is essential first to generate functional human cardiomyocytes (CMs). The use of these cells in drug discovery and toxicology studies would also be highly beneficial, allowing new pharmacological molecules for the treatment of cardiac disorders to be validated pre-clinically on cells of human origin. Of the possible sources of CMs, induced pluripotent stem (iPS) cells are among the most promising, as they can be derived directly from readily accessible patient tissue and possess an intrinsic capacity to give rise to all cell types of the body 1. Several methods have been proposed for differentiating iPS cells into CMs, ranging from the classical embryoid bodies (EBs) aggregation approach to chemically defined protocols 2,3. In this article we propose an EBs-based protocol and show how this method can be employed to efficiently generate functional CM-like cells from feeder-free iPS cells.

Introduction

Historically, the investigation of the genetic and molecular mechanisms driving human development and disease has been based on the generation of genetically modified animal models. However, numerous human phenotypes fail to be successfully replicated in mice, mainly because of the biological differences existing between the two species. On the other hand, access to human tissues may be limited and often do not allow enough material to be obtained for in-depth experimental studies. The field of cardiovascular biology suffers from both these limitations: the physiology of the human heart is significantly different from that of the mouse, and a significant quantity of h....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Feeder-free Maintenance and Passaging of Human iPS Cell Lines

  1. Prepare the Matrigel-coated dishes. Thaw one vial of human ESC-qualified Matrix on ice for one hour and dilute it in 25 ml DMEM-F12 medium. Add 1 ml to each 35 mm plate (or equivalent amounts per surface area if other dishes are used), keeping everything on ice and ensuring that all plates and tubes are pre-cooled. Cover plates with aluminum foil.

Note: Matrigel stock concentrations vary by the batch. Dilution instructions are indicated on the data sheet.

  1. Keep plates on ice overnight and remove from ice the next day. ....

Access restricted. Please log in or start a trial to view this content.

Results

In our studies we generated CMs from several iPS cell lines. These lines were initially generated on an MEF feeder layer but were immediately placed on Matrigel using a defined medium (either mTESR1 or Nutristem). Various assays were used to verify maintenance of the morphological properties, the expression of markers typical of pluripotent cells (OCT-4, SSEA4 and TRA1-60) and their genome stability (Figure 1).

Induction into the cardiac lineage was triggered by aggregation of.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Pluripotent stem cells have the potential to differentiate spontaneously into CMs, albeit with low efficiency and high variability among lines. The development of novel induction methods has therefore focused on improving the efficiency of the process and moving toward more defined protocols. However, most of these new differentiation methods are quite complex, requiring elaborate culture conditions, fine control of timing and concentration of reagents, and treatment with expensive cytokines and growth factors. Also, dif.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

No financial interests to disclose.

Acknowledgements

BS was supported by University of Milan-Bicocca Summer Student Research Training Program; research was supported from funds of the Italian Ministry of Health and Italian Ministry of Education, University and Research and Fondazione Humanitas to GC; we thanks Michael V.G. Latronico for critically reading the manuscript.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Media and Reagents
Human ESC-qualified MatrixBD Biosciences354277Thaw the 5 ml bottle at 4 °C on ice O/N, aliquot in pre-chilled cryo-tubes on ice, according to the data sheet dilution instructions and store at -20 °C .
Fibronectin, from human plasma, 0.1% solutionSigmaF0896-2MGWorking concentration: 5 μg/cm2
LamininSigmaL2020-1MGWorking concentration: 5 μg/cm2
PBS (no Mg and Ca), 10XLonzaBE17-515F
PBS (with Mg and Ca), 10XBio SeraXC-S2067/500
Dispase II, neutral protease, grade IIRoche4942078001Stock: 10 mg/ml in DMEM-F12 at -20 °C, working solution: 1 mg/ml in PBS (no Mg/Ca)
Trypsin/EDTA, 0.5%SigmaT3924
Collagenase type 2Worthington4176Dilute to 480 U/ml (e.g. 1.6 mg/ml) in PBS with Mg and Ca
DMEM-F12Life Technologies21331-020
Knockout DMEMLife Technologies10829-018
Knockout Serum Replacement (KSR)Life Technologies10828-028Thaw at 4 °C, aliquot and store at -20 °C
F–tal Bovine Serum (origin South America)Invitrogen10270-106Batches should be tested for their cardiogenic potential. Thaw at 4 °C, heat-inactivate at 56 °C for 30 min, aliquot and store at -20 °C
PenStrep, penicillin-Streptomycin, 100XLife Technologies15140-122
GlutaMAX, 100XLife Technologies35050-038
MEM NEAA, 100XInvitrogen11140-135
N2 supplement, 100XLife Technologies17502-048
B27 supplement, 50XLife Technologies12587-010
2-mercapt–thanolInvitrogen31350-010
Gelatin, from porcine skinSigmaG1890-100GMake stock at 1% in water, store at -20 °C. Dilute to 0.1% in PBS and keep at 4 °C
mTeSR1Stem Cell Technologies5850Combine Supplement 5X with the basic medium, aliquot and store at -20 °C. Do not keep complete medium at 4 °C for more than 1 week
Nutristem hESC XFStemgent from Biological Industries05-100-1AThaw at 4 °C O/N, aliquot and store at -20 °C until use. Aliquots may be kept at 4 °C for no more than a week.
mFreSRStem Cell Technologies5853
Ascorbic acidSigmaA4544-25GPrepare stocks at 10 mg/ml in water. Store aliquots at -20 °C in the dark. Add to EBM at the final concentration (500X)
Plasticware
35 mm culture dishesBecton Dickinson353001
Cell scraperCorning Incorporated3008
12-well platesBecton Dickinson353043
Permanox 2-well chamber slidesThermo Fisher Scientific177437
Glass 2-well chamber slidesThermo Fisher Scientific177380
6-well plates, ultra-low-attachment surfaceCorning Incorporated3471
18G needleBecton Dickinson304622
Glass pasteur pipettes, 230 mmVWR International612-1702
2.5 ml syringeBecton Dickinson300188
Equipments
IVF WorkstationKSystem, by Nikon
Nikon SMZ1500 StereomicroscopeNikon

References

  1. Di Pasquale, E., Latronico, M. V., Jotti, G. S., Condorelli, G. Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. Gene Therapy. 19, 642-648 (2012).
  2. Laflamme, M. A., Murry, C. E. Heart regeneration. N....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Embryoid Bodies AggregationFeeder-free ConditionsCardiomyocyte DifferentiationImmunofluorescence MicroscopyEnzymatic DigestionFibronectin CoatingCardiac TroponinStromal Vascular Fraction